Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and IBI305 in Advanced Hepatocellular Carcinoma
NCT04072679Phase 1Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Chinese Academy of Medical Sciences. Started Oct 2018; status: completed.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04072679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072679.